GEHC Is Down 27% Over 660 Days. What History Says.

GEHC Is Down 27.4% Over 663 Days. What History Says.

GE HealthCare Technologies Inc. (GEHC) is down 27.4% from its all-time high as of July 31, 2026, and has been falling for 663 days. The Drawdown Severity Score™ stands at 5.6, placing it in the Strong, red zone. In 2 comparable prior drops of this depth, the stock took an average of 255 days to recover.

Analyzing the Current 27.4% Drawdown

The current price of $68.02 represents a deep departure from the all-time high of $93.65. This decline of 27.4% has developed over a period of 663 days, indicating a prolonged period of selling pressure rather than a sudden market shock. As of July 31, 2026, this extended duration has triggered a transition from the yellow zone to the red zone.

Our proprietary severity score has reached 5.6, which designates the current correction as Strong. This level indicates that the stock is experiencing an extended period of underperformance that exceeds its typical historical pullback patterns. The transition to the red zone suggests that the supply of shares continues to outpace demand over a multi-month horizon.

Understanding the speed and depth of this decline is critical for risk management. A drawdown that lasts 663 days can exhaust patient capital and lead to institutional tax-loss selling. We track these metrics to help investors identify when a normal correction crosses the line into an extended structural decline.

How This Sell-Off Compares to GEHC History

To put the current correction into perspective, we must analyze the historical trading behavior of GEHC. Across 19 total historical drawdown events, the stock has established a highly consistent baseline for corrections. On average, GEHC experiences a maximum drawdown of -4.8% with an average drawdown duration of 33 days.

The current 27.4% drop is far more severe than these historical averages. Our data shows that GEHC has dropped by 20% or more only 2 times in its trading history. This low frequency highlights how unusual the current market environment is for the medical technology company.

However, investors must consider a small sample size caveat when analyzing these figures. Because GEHC has only 2 comparable historical events of this magnitude, the statistical averages may not fully predict future performance. In those 2 prior instances, the average duration of comparable drops was 255 days.

The current drawdown has lasted 663 days, which is more than double the historical average of 255 days for deep corrections. This massive divergence suggests that the factors driving the current sell-off are more persistent than those encountered during previous declines.

Comparing Historical Drawdown Events

Comparing the current market data against historical benchmarks reveals the extreme nature of this correction. The table below outlines how the current active drawdown compares to both the overall historical average and the subset of deep corrections.

The data in this table shows that the current correction is an extreme statistical outlier. The duration of 663 days is twenty times longer than the average historical drawdown of 33 days. Even when compared to the 2 prior deep corrections, the current timeline is extended by 408 days.

This prolonged duration indicates that the stock has failed to find a stable price floor. In typical pullbacks, buyers step in quickly to support the stock within approximately 33 days. The lack of a strong rebound over 663 days suggests that institutional accumulation has remained subdued.

Catalysts and Recent News Context

To understand why this drawdown has persisted for 663 days, we must examine the fundamental news driving the company. Recent corporate developments present a complex picture of operational success mixed with market skepticism.

According to Seeking Alpha, GEHC stock experienced positive momentum after reporting a Q2 2026 earnings beat. Barron's also reported that the stock rose following the earnings release, pointing to solid profit gains as the primary driver. These short-term positive reactions show that the company continues to generate robust operational results.

However, these positive earnings surprises have not been enough to break the long-term downward trend. A report from Simply Wall St highlighted that the stock faces persistent margin pressure despite its solid Q2 growth. This margin pressure suggests that rising costs may be offsetting revenue gains, which concerns long-term investors.

Furthermore, Yahoo Finance noted that while the stock looks reasonable on earnings, it appears stretched on fair value. This valuation mismatch can prevent institutional buyers from committing large amounts of capital, keeping the stock in its 27.4% drawdown.

Legal challenges are also impacting investor sentiment. According to TradingView, a securities fraud investigation into the company by Glancy Prongay Wolke & Rotter LLP is ongoing. This investigation, which urges shareholders who lost money to contact the firm, creates an additional layer of reputational and financial risk.

Statistical Significance of the Drawdown Severity Score™

The Drawdown Severity Score™ is a proprietary metric designed to measure the intensity of an asset's decline. By scoring the current event at 5.6, our model places GEHC in the Strong, red zone category. This score indicates that the combination of depth and duration is highly unusual for this specific asset.

A severity score of 5.6 is generated when a stock remains in a deep drawdown far longer than its historical distribution suggests. While a -27.4% decline is common for high-beta technology stocks, it is rare for a stable healthcare technology provider. The extended 663-day timeline heavily weights the score, reflecting a persistent lack of upward momentum.

Our data shows that when large-cap healthcare stocks enter this level of severity, recovery is rarely immediate. The transition into the red zone often leads to a period of base-building where the stock trades sideways. This process allows the market to digest negative news and establish a more sustainable valuation floor.

Risk Management and Future Scenarios

For investors tracking GEHC, the transition to the Strong, red zone provides important risk boundaries. Historical averages suggest that deep drawdowns for this stock have eventually resolved, but the current 663-day timeline represents uncharted territory.

Because of the small sample size of 2 comparable events, historical averages must be interpreted with caution. We cannot assume that the stock will automatically revert to its historical recovery patterns. Instead, the data suggests that the stock is experiencing a unique structural repricing.

Managing risk in the red zone requires monitoring whether the stock can stabilize above its current price of $68.02. A stabilization would be the first step toward reducing the Drawdown Severity Score™ and moving back toward the yellow zone. Continued margin pressure or further legal developments could, conversely, extend the duration of this correction.

We will continue to monitor the exact metrics of this decline as new trading data becomes available. Keeping a close eye on these objective numbers helps investors strip emotion out of their decision-making process.